Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What's Poolbeg's excuse?
It's such a 'bizarre excuse' that I forwarded it to the Business Editor of the Irish Independent.
It really hope he publishes it
I’ve heard that the dog ate the Chim data. Lol
Yes it is a “bizarre excuse”. Sort of on par with the dog ate my homework
What a bizarre excuse for the sell off. Furloughed people who are now back in work and so selling their "hobby shares" willy nilly? Really?
No actual news on these spin offs which are supposed to be what is holding us back/about to release the amazing potential of the business? What a poor response. Just adds fuel to the blarney-itis fire. But thank you for obtaining it.
Hallsworthy. Yes, all written by Walbrook. Copied and pasted the complete email.
It is a reminder that the fundamentals, leadership and potential, which should always be the reasons one invests in a company, remain strong and the current sp simply does not reflect this. This is an undervalued company and the market will recognize this in time. I also believe once the spin outs are complete more II's will come on board. Patience and nerve are required - essential investment traits. The impatient and nervous are currently being flushed out - not necessarily a bad thing.
Should have said look at the spread here too -games afoot
As soon as the support line was breached we are heading for 15p next support.
Thanks Timber - will have re-read & think.
In general nothing has changed on fundamentals - I averaged up - aaargh. Waiting to top up,as the current value is just bollax
Is that all written by Walbrook? It's actually quite an impressive effort compared to their (and their competitors) usual patter and it does put me at ease to read through all of that and know the fact we already have ~65% (someone check the figure for me) of 2022 figures banked should put anyone at ease. It also makes me think we are more likely to have 'surprise' RNS in future rather than be completely broadcast by Cathal in interviews, which is a much better approach.
It would be really useful to get SOME sort of update or communication from the company laying out how various things are going, it just feels neglectful at the moment that they are doing nothing to provide support and improve sentiment.
This was missing from the beginning of the previous post:
Expansion of COVID-19 characterisation study 20 further volunteers (14 July)
Continued…..
20 further volunteers (14 July)
Unfortunately, the excellent progress made by the Company in recent months has been hampered by retail selling, we all know the small cap AIM stocks have been having a difficult six months across the board and Open Orphan along with many other similar stocks on AIM have found a significant amount of unexpected retails selling over that period. There is some belief that some of this market selling is to do with a large group retail investors who entered the market in April / May 2020 and many of whom had been furloughed at home and used their time very productively while furloughed to actively research, follow, and invest in small AIM stocks with promise, particularly those with potential upside as a result of the pandemic. As a result of the wind down of furlough, a large amount of this group of new retail have returned to work and as such don’t have time to research small cap stocks and as such, many are cashing in the profits and leaving the market and hence that is our belief what is driving the retail sell off in the past six months.
Currently, management does not believe the share price represents the true value of the Company and its growth potential and going forward it believes that its strategy of growing its core business and monetising non-core assets will result in value for shareholders being realised.
Kind regards,
Louis
I have this morning received the following reply to my email sent to Walbrook yesterday expressing my concerns and those of other committed LTH holders on this board regarding the continued fall in the sp:
Thank you for your feedback which will be passed onto the Company.
Cathal has received feedback from investors and advisers on investor communications and he will adapt his approach. Going forward, Cathal does not want his own considerable optimism regarding the Company, which is outlined by his recent share purchase, to cause undue expectation in the market – but instead wait for these milestones to come to fruition and update shareholders accordingly.
Under Cathal’s leadership, however, the Company has transformed into a cash generative business regularly delivering substantial contracts and significant value for shareholders. 2021 has been a transformative year for the business, with EBITDA profitability confirmed at the interim stage which is expected to continue to the year end. It is worth noting that hVIVO and Venn were both significant loss-making businesses until Open Orphan acquired them. Both are now profit-making businesses with significant growth potential and synergies.
The highlights from the Company’s transformative 2021 are outlined below:
Substantial growth in core services business
· £7.5m RSV contract (26 March)
· Significant HRV & Influenza contract w/ AIM Imm (9 July)
· £8.1m Asthma contract (24 August)
· £5.7m Influenza contract (20 September)
· £5.1m RSV contract (17 November)
Announceable contracts for Venn
· Contract renewal w/ top-3 pharmaceutical client (6 January)
· Contract extension w/ Carna Biosciences (1 February)
· New contract w/ Oxford BioTherapeutics (9 March)
· New contract for Breda office (14 July)
· DNDi Phase II trial support (29 July)
· £1.5m contract renewal for Venn Life Sciences (15 November)
Capacity increase
· New 19-bedroom quarantine facility (3 February)
· Expansion of volunteer recruitment centres (20 January)
· COVID study taking place in 19-bed quarantine facility at Royal Free
Improved offering w/ expanded portfolio of human challenge models and expertise
· Added a Malaria Human Challenge model (9 August)
· Acquisition of CHIMagents completed, now integrated into company (14 July)
· Significant CRO experience added to the board in Yamin 'Mo' Khan (13 October)
Progress on monetisation of non-core assets
· Spin out of Poolbeg Pharma / £25m raise w/ £50m valuation (14 July)
· Launch of Disease in Motion (9 April)
· Imutex positive Phase I study results (19 November)
Seized covid opportunity
· Ethics approval for world's first COVID-19 characterisation study (17 February)
· £3m contract to manufacture COVID-19 challenge virus (10 May)
·